Advanced Chemistry Development
and Milestone Development Services
Dr. Mike Lee is President of Milestone Development Services. He has actively participated in the growth of new technologies and their integration into drug development. He is currently involved with consulting, workshops, and symposia to connect industry needs with innovative technologies and solutions. Dr. Lee has extensive experience with pharmaceutical analysis
and drug development. He has pioneered the application of LC/MS in different phases of drug development for research in biomolecules, natural products, drug metabolites, impurities, and degradants.
Dr. Lee is a founder of the Symposium on Chemical and Pharmaceutical Structure Analysis (CPSA). This unique event highlights industry-related applications and features sessions promoting interaction and discussion. Industry scientists and professionals focus on needs, issues, and
analytical performance benchmarks necessary for accelerated drug development. Prior
to founding Milestone Development Services, Dr. Lee was with Bristol-Myers Squibb from 1987-1998. As director of analytical research and development,
Dr. Lee was responsible for departments in several research facilities
providing MS, NMR, IR, HPLC, CE, and physical chemistry support. Under his
direction, novel analytical strategies for preclinical development facilitated the shortening of IND development from 2 years to 6 months. He led interdisciplinary teams responsible for rapid analysis of discovery leads and preclinical drug candidates that contributed to the Food & Drug Administration approval of Buspar, and Serzone, and the accelerated development and approval of TAXOL.
Mike Lee is the author of the recent publication "Spectroscopic Methods of Analysis - Mass Spectrometry" in Dekker's Encyclopedia of Pharmaceutical Technology. This is an excellent article, which will be a good education for anyone wanting to understand today's applications of MS at a higher level.
We look forward to working with Dr. Lee as an advisor and consultant in regards to the development of our MS Module of ACD/SpecManager.
|
